Pancreatic Cancer Vaccine Shows Interception Promise in High-Risk Patients
(MedPage Today) -- A peptide vaccine targeting KRAS mutations in pancreatic cancer showed preliminary evidence of activity in a small study of high-risk patients. The vaccine elicited KRAS-specific T-cell responses in 18 of 20 patients with mutations...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

